Trend/Momentum: MACD histogram is negative (-0.148) and negatively expanding → bearish momentum still building.
RSI (6): 32.805 → weak/near-oversold short-term condition, but not a confirmed reversal signal on its own.
Moving averages: converging → potential basing, but not yet a bullish crossover/expansion.
Levels: Pivot 9.416 (overhead), Resistance R1 10.204; Support S1 8.628 then S2 8.141. With price at 8.83, KLRS is trading beneath the pivot and closer to support.
Pattern-based outlook (provided): indicates a high probability of a move toward ~7.08 in the next day / ~8.07 in the next week (bearish near-term bias).
Positive Catalysts
Analyst stance is strongly constructive: Buy/Outperform initiations/raises with high targets ($19 and $26).
Lead program TH103 in wet AMD cited for early efficacy and potential durability; potential expansion into additional retinal indications (diabetic retinopathy/DME/RVO) is a longer-run upside lever.
Price is near support (8.63 area), which can sometimes attract dip-buying if it holds.
Neutral/Negative Catalysts
Model/pattern signal suggests elevated probability of near-term downside.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 0 (no operating revenue), unchanged YoY.
Net income: -$11.894M, down 68.77% YoY (loss widened).
EPS: -0.64, down 97.73% YoY (deterioration).
Takeaway: fundamentals show continued cash burn/loss expansion, so the stock is primarily catalyst/clinical-sentiment driven rather than earnings driven.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: improving/very bullish.
2025-12-18: Citizens raised PT to $26 from $20; maintained Outperform; highlighted strong early efficacy/durability signals for TH103 and framed weakness as a buying opportunity.
2025-12-23: Chardan initiated at Buy with $19 PT; emphasized commercial potential in wet AMD and expansion opportunities.
Wall Street pros: strong enthusiasm around TH103’s early profile and larger retinal market opportunities.
Wall Street cons: the bull case depends on clinical/regulatory execution; without near-term catalysts, the stock can trade off technicals and funding concerns.
Wall Street analysts forecast KLRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KLRS is 16.67 USD with a low forecast of 5 USD and a high forecast of 26 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast KLRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KLRS is 16.67 USD with a low forecast of 5 USD and a high forecast of 26 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.350
Low
5
Averages
16.67
High
26
Current: 8.350
Low
5
Averages
16.67
High
26
Chardan
NULL
to
Buy
initiated
$19
AI Analysis
2025-12-23
Reason
Chardan
Price Target
$19
AI Analysis
2025-12-23
initiated
NULL
to
Buy
Reason
Chardan initiated coverage of Kalaris Therapeutics with a Buy rating and $19 price target. The firm cites the commercial potential of the company's lead candidate TH103 in wet age-related macular degeneration for the Buy rating. Kalaris has further opportunities to expand into diabetic retinopathy, diabetic macular edema, and retinal vein occlusion, the analyst tells investors in a research note.
Citizens
Jonathan Wolleben
Outperform
maintain
$20 -> $26
2025-12-18
Reason
Citizens
Jonathan Wolleben
Price Target
$20 -> $26
2025-12-18
maintain
Outperform
Reason
Citizens analyst Jonathan Wolleben raised the firm's price target on Kalaris Therapeutics to $26 from $20 and keeps an Outperform rating on the shares. TH103 demonstrated a strong early efficacy profile, with a mean 10-letter Best Corrected Visual Acuity improvement, a 129 microm central subfield thickness reduction one month after a single dose, and 31% of patients maintaining benefit for six months without anti-VEGF rescue, suggesting meaningful durability, the analyst tells investors in a research note. The firm views any weakness on intraocular inflammation events as an attractive buying opportunity.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KLRS
